Thermo Fisher Scientific Partners with Medidata Acorn AI to Optimize Clinical Research Site Selection and Speed Patient Enrollment in Clinical Trials

Rhea-AI Summary

Thermo Fisher Scientific has announced a multiyear partnership with Medidata Acorn AI to develop PPD TrueCast, an advanced platform for enhancing clinical trial performance.

This application integrates machine learning and predictive analytics, leveraging data from over 40,000 trial sites and 50,000 investigators. It aims to optimize site selection, trial enrollment, and study cycle times, potentially reducing Phase III study enrollment by 1.5 months and improving milestone forecasting accuracy by 30%.

Positive

• Partnership with Medidata Acorn AI to develop TrueCast platform.
• TrueCast combines machine learning with extensive clinical trial data for improved trial performance.
• Potential to reduce Phase III study enrollment by 1.5 months.
• Expected 30% increase in accuracy of forecasting trial milestones.

Negative

• None.

PPD TrueCast combines machine learning, predictive analytics and clinical trial data to advance trial performance and quality

WILMINGTON, N.C.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc., the world leader in serving science, announced a multiyear partnership with Medidata Acorn AI, a Dassault Systèmes company leading the digital transformation of life sciences. Through this partnership, the PPD clinical research business of Thermo Fisher has collaborated with Medidata to develop PPD TrueCast, a comprehensive enterprise application combining extensive patient recruitment and site performance data with predictive models and advanced analytics. Offering one of the industry’s most wide-ranging representations of real-time site performance combined with machine learning, this new platform gives pharmaceutical and biotech companies actionable insights to optimize clinical research site selection, trial enrollment and study cycle times.

“The clinical trial industry continues to demand new tools in big data and predictive analytics to improve trial planning and execution and accelerate clinical trials,” said David M Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific. “As a result of the vast site-level data amassed by PPD and Medidata, customers now have even greater visibility into how a trial is performing for any study our clinical research business is helping them run. We already have successfully deployed these machine learning-based insights to give us a competitive site selection advantage in the crowded trial landscape.”

TrueCast creates value for biopharmaceutical companies at multiple points along the clinical trial life cycle by delivering deep site-performance data in real time from an extensive global footprint of trial sites. The platform utilizes advanced artificial intelligence (AI) models to forecast cycle times and enrollment performance, enabling simplified scenario planning and optimized country and site selection. During a study’s enrollment period, TrueCast automatically tracks study performance and predicts enrollment risk. When mitigation is needed, the application provides access to real-time site performance metrics to identify high-performing sites.

“AI and advanced analytics play an increasingly critical role in a rapidly changing clinical trial environment," said Fareed Melhem, senior vice president, Medidata Acorn AI. "We’re delighted to be working side by side with Thermo Fisher’s clinical research business to combine our technology, data and expertise. Together, we are now offering companies new ways to rethink their clinical trials through access to live, cross-industry site performance data.”

The TrueCast platform builds upon one of the industry’s most extensive site-level data assets. Thermo Fisher’s clinical research business reflects data from 40,000 sites, 50,000 investigators and more than 2,000 studies. Medidata’s unique datasets have been generated from its experience with more than 26,000 clinical trials and nearly 8 million patients in more than 140 countries across the globe. As a result of this powerful dataset and proprietary machine learning-based site recommendation models, the average Phase III study enrollment period was reduced by an average of 1.5 months in retrospective trial simulations when site recommendation models were utilized to select a portion of the country and site footprint. Furthermore, Thermo Fisher expects to realize a 30% increase in the accuracy of forecasting trial milestones.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220207005491/en/

Media:

Randy Buckwalter

Thermo Fisher Scientific

+1 919-456-4425

randy.buckwalter@ppd.com

Source: Thermo Fisher Scientific Inc.

FAQ

What is the purpose of the TrueCast platform developed by TMO?

The TrueCast platform aims to enhance clinical trial performance by optimizing site selection, trial enrollment, and study cycle times using machine learning and predictive analytics.

How will the partnership between Thermo Fisher and Medidata impact clinical trials?

This partnership is expected to provide actionable insights that can significantly improve trial planning and execution, leading to shorter enrollment periods and better resource allocation.

When was the partnership between Thermo Fisher and Medidata announced?

The partnership was announced in February 2022.

What are the anticipated benefits of using TrueCast in clinical trials for TMO?

TrueCast is expected to reduce the average Phase III study enrollment period by 1.5 months and increase the accuracy of forecasting trial milestones by 30%.